论文部分内容阅读
证券界人士近日分析中药业上市公司前景时认为,尽管“人类基因组草图”的完成,生物制药特别是基因制药,再次成为上市公司投资的热点,但综合分析表明,我国生物制药业的发展将比较曲折,而中药业却面临难得的发展机遇,介入该领域的上市公司将从中获益。
In the recent analysis of the prospect of listed TCM companies, the securities industry believes that despite the completion of the “Human Genome Sketches”, biopharmaceuticals, especially gene pharmaceuticals, once again become a hot spot for listed companies to invest in. However, a comprehensive analysis shows that the development of China’s biopharmaceutical industry will More twists and turns, while the Chinese medicine industry is facing rare opportunities for development, intervening in the field of listed companies will benefit.